Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy

Brachytherapy

Volumn 8, Issue 1, 2009, Pages 45-51

  Ghadjar, Pirus ^a   Keller, Tamara ^a   Rentsch, Cyrill A ^a   Isaak, Bernhard ^a   Behrensmeier, Frank ^a   Stroux, Andrea ^b   Thalmann, George N ^a   Aebersold, Daniel M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

HDR brachytherapy; Monotherapy; Prostate cancer; Urethral dose

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DYSURIA; GASTROINTESTINAL TOXICITY; HEMATURIA; HORMONAL THERAPY; HUMAN; MALE; MONOTHERAPY; POLLAKISURIA; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SEXUAL FUNCTION; SURVIVAL RATE; TREATMENT OUTCOME; URINE INCONTINENCE; URINE RETENTION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; IRIDIUM RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; URETHRA;

EID: 58149490954     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2008.09.004     Document Type: Article

References (23)

1. Bracarda S., de Cobelli O., Greco C., et al. Cancer of the prostate. Crit Rev Oncol Haematol 56 (2005) 379-396
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2006 56 (2006) 106-130
3. Ragde H., Korb L.J., Elgamaal A., et al. Modern prostate brachytherapy: prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 89 (2000) 135-141
4. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with I-125 brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
5. Eulau S.M., Van Hollebeke L., Cavanagh W., et al. High dose rate iridium 192 brachytherapy in localized prostate cancer: Results and toxicity with maximum follow-up of 10 years. [Abstract]. Int J Radiat Oncol Biol Phys 48 Suppl. (2000) 149
6. Martinez A.A., Gustafson G., Gonzalez J., et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 316-327
7. Pellizzon A.C., Nadalin W., Salvajoli J.V., et al. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol 66 (2003) 167-172
8. Hiratsuka J., Jo Y., Yoshida K., et al. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 684-690
9. Galalae R.M., Martinez A., Mate T., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1048-1055
10. Demanes D.J., Rodriguez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California Endocurietherapy's 10 year results. Int J Radiat Oncol Biol Phys 61 (2005) 1306-1316
11. Yoshioka Y., Nose T., Yoshida K., et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 48 (2000) 675-681
12. Martinez A.A., Pataki I., Edmundson G., et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 49 (2001) 61-69
13. Rodriguez R.R., Demanes D.J., and Altieri G.A. High-dose-rate (HDR) monotherapy for early stage prostate cancer: preliminary results. [Abstract]. Brachytherapy 2 (2003) 62
14. Martin T., Baltas D., Kurek R., et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 180 (2004) 225-232
15. Grills I.S., Martinez A.A., Hollander M., et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171 (2004) 1098-1104
16. Yoshioka Y., Nose T., Yoshida K., et al. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys 56 (2003) 213-220
17. Yoshioka Y., Konishi K., Oh R.J., et al. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol 80 (2006) 62-68
18. Corner C., Rojas A.M., Bryant L., et al. A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) [in press]
19. Sobin L.H., and Wittekind C.H. The prostate. In: Sobin L.H., and Wittekind C.H. (Eds). TNM Classification of Malignant Tumors (2002), Wiley-Liss, New York 184-187
20. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
21. Brenner D.J., and Hall E.J. Fractionation and protraction for radio-therapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
22. Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62 (1989) 679-694
23. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116